FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis
GlobalData has released its new PharmaPoint Drug Evaluation report, FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available. FluBlok is being developed by the Protein Sciences Corporation (PSC), headquartered in Meriden, Connecticut in the US. FluBlok is the leading vaccine candidate in PSC’s vaccine portfolio that also focuses on pandemic influenza, SARS and flu vaccine adjuvants. The trivalent vaccine consists of recombinant hemagglutinin protein, from H1, H3 and B strains, that are propagated in a baculovirus expression vector system in insect cells (FDA Briefing document). The vaccine is a first-in-class product that is the first vaccine to use an insect cell-based manufacturing system in the US.
Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on FluBlok including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for FluBlok in the US from 2011 to 2022.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for seasonal Influenza.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of FluBlok performance
Obtain sales forecast for Tabalumab from 2011 to 2022 in (the US, France, Germany, the UK, Italy, Spain, Japan and Australia)